Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27869627 | 0.97 | LMNA (0.46) | LMNAOPRM1DNM1PLA2G1BPLA2G2A | |
| SCHEMBL1163264 | 0.97 | LMNA (0.46) | LMNAOPRM1DNM1PLA2G1BPLA2G2A | |
| SCHEMBL10528718 | 0.97 | LMNA (0.46) | LMNAOPRM1DNM1PLA2G1BPLA2G2A | |
| SCHEMBL4030013 | 0.97 | LMNA (0.46) | LMNAOPRM1DNM1PLA2G1BPLA2G2A | |
| SCHEMBL6155980 | 0.97 | LMNA (0.46) | LMNAOPRM1DNM1PLA2G1BPLA2G2A | |
| SCHEMBL27605329 | 0.92 | — | — | |
| SCHEMBL27611845 | 0.80 | — | — | |
| SCHEMBL10971025 | 0.78 | SPHK1 (0.43) | TSHRTHRB | |
| SCHEMBL27587383 | 0.75 | LMNA (0.44) | LMNAOPRM1DNM1PLA2G1BPLA2G2A | |
| SCHEMBL676575 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | LMNA 4351/4885OPRM1 70/4885DNM1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.